biocarbon ureterostomy device is a stoma1 prosthesis for upper tract urinary diversion that has had preliminary successes in animal and human trials in Europe and Peru. Implantation of a pure carbon stoma1 prosthesis offers the potential advantages of high biocompatibility, lack of encrustation, and elimination of stoma1 stenosis which is frequently associated with cutaneous ureterostomy. Nine biocarbon ureterostomy devices were implanted from August, 1984 through July, 1985. Although successful implantation was achieved in 2 patients, the complication rate was high. The biocarbon ureterostomy device has potential as an alternative form of urinary diversion. However, significant problems need to be remedied before it can be recommended for routine clinical application.
The variety of urinary diversions currently in use by urologists are testimony to the absence of a simple, reliable procedure. Because of this, we have evaluated a vitreous carbon prosthesis for cutaneous ureterostomy in 9 patients requiring urinary diversion. Pure carbon in the vitreous or glassy form was first developed and characterized in England in 1963 as an outgrowth of space exploration. The remarkable characteristics of this pure carbon material suggested its potential biologic applicability. Vitreous carbon is a hard, impermeable solid that is *Sponsored by American Medical Systems, Minnetonka, Minnesota. chemically inert at ambient temperature and shows no galvanic activity with saline solutions. ' Mooney, Hartmann, and McNeal' used a pure carbon percutaneous electrical connector and found it to be biologically inert and free of infection for more than two years. Longley and associates2 evaluated a vitreous carbon urostomy device for vesicostomy and ileal bladder stomata in dogs and documented its feasibility by demonstrating good short-term function. Harzmann, Bichler, and Ideler3 reported the successful use of biocarbon urinary conduits for vesicostomy stomata in 6 patients for up to fifteen months. The stomas resulted in urinary continence without encrustation and with good wound healing. B A carbon prosthesis was also evaluated in several animal species as a stoma1 device for ureterocutaneous anastomoses.4 A functioning conduit was obtained in 7i percent of the implants. Eleven of 48 stoma1 prostheses were unsuccessful. Causes of stoma1 failure included poor healing, parastomal inflammation, urinary extravasation, and severe encrustation.
Pow-Sang and associates5 implanted bicarbon ureterostomy devices in 20 patients with uterine cervical or bladder cancer. Only 1 patient was alive at the time of the report. She had a functioning implant at one year after two reimplants. Of the remaining patients, 18 died of carcinomatosis and 1 had a cardiac arrest eleven days postoperatively. Eleven implants were functioning at the time of death. Urinary fistulas developed in 7 patients.
A clinical trial with a biocarbon ureterostomy prosthesis was begun in the United States in 1984. Results of this trial are reported.
Material and Methods
Vitreous (glassy) carbon is the primary component of the biocarbon ureterostomy device. It is composed of 99.9 percent pure carbon, and its hardness and impermeability enable it to accept a high surface polish. The biocarbon ureterostomy device is a rigid, transcutaneous prosthesis providing a nonstenosing route for urine drainage from the ureters. The device has a tapered inner spout with an internal circumference of 11.5 F that can be intubated into the ureter. The larger outer spout has a rim to facilitate a leak-free attachment to a drainage device. In addition there is a wide flange in the device which is inserted between the abdominal muscle and external fascia for fixation. The inner spout is covered with Dacron fabric to promote tissue ingrowth ( Fig. 1 ). Nine people received biocarbon implants from August 30, 1984 to July 17, 1985. Seven were implanted with devices with a straight inner spout, and two were implanted with devices with a curved inner spout. Indications for the devices included cystectomy or ureteral obstruction.
Transureteroureterostomy was performed in the 5 patients who had cystectomy. An indwelling single J ureteral stent through the conduit was routinely employed for up to six weeks after the implantation. Postoperatively, the patients were followed closely and were specifically monitored for infection, encrustation, urinary tract obstruction, fistula,
FICUHE 1. BioCarbon uretrrostomy device consists of tapered. flanged. carbon tube with Dacron rcrap.
and biocompatibility.
Of the 4 patients who died of their cancer, postmortern examination of the biocarbon device was not possible in 2. All five devices removed for infection and fistula underwent pathologic examination.
Results
Nine patients with a mean age of sixty-four years (range 56 to 71 years) underwent single biocarbon ureterostomy implantation. Indications for the device included cystectomy for bladder cancer (5), unilateral obstruction of the ureter (2), and stenosis of a previous cutaneous ureterostomy (2). The 5 cystectom!, patients all had transureteroureterostomy at the time of surgery. The mean and median duration of implantation was one hundred thirty days and seventy-six days, respectively. A summary of the results is listed in Table I .
Two patients (LB and WE) died of neoplastic disease with functioning devices. The duration of device implantation in these individuals was thirty-four and one hundred seventy three days. Their devices were not retrieved for examination. Two other patients died of neoplasm but had complications with their dcavices. One (WR) had a satisfactorily functioning device. However, for the last two weeks of his life ascitic fluid leaked around the device requiring the use of a urostomy bag over the prosthesis. In the other patient (VL) progressive hydronephrosis developed secondary to lymphocele obstruction which was drained six months after implantation.
A sinus near the ureterostomy device started leaking urine six and one-half months after implantation and was managed by his wearing a urostomy bag over the device for the last five months of his life.
In the remaining 5 patients, the device was removed because of device-related complications and urinary diversion was accomplished by other means (4 ileal conduits and 1 cutaneous ureterostomy).
Three devices were removed because of urinary fistulas. One patient (FJ) had a device implanted into a stenosed cutaneous ureterostomy.
The device was subsequently removed because of ureteral obstruction proximal to the device and Pseudomonas skin infection around the prosthesis. One patient (LC) had an excess of subcutaneous adipose tissue which was partially excised at the time of his implantation.
Nevertheless, the device subsequently retracted below the skin level followed by the development of soft tissue infection requiring removal of the prosthesis.
Primary problems were the development of urinary fistulas and soft tissue infections caused by a variety of organisms.
Inadequate spout length of the device contributed to a poor result in at least 1 patient (LC). Adequate ingrowth of tissue into the Dacron sheath was generally poor in the devices that were examined (Fig. 2) . However, the successful devices were not re-
FIGURE 2. Zone of attachment of ureter to inner uxap Dacron is show>n in device explanted after six weeks. Urothelium is marked by arrow. Little collagen in Dacron inner wrap material. (Masson trichrome stain.)
trieved for follow-up study. An additional technical concern was the development of significant encrustation clogging the indwelling single J ureteral stent in 2 patients. Furthermore, a high incidence of poor tissue ingrowth into the Dacron covering the biocarbon was noted. Whether these represent separate events or are a consequence of one another is unclear. Infections not only may have an adverse effect on wound healing but also may increase the stone-forming ability of urine. Despite the high degree of inertness of biocarbon, encrustation was noted on two devices. In both cases, the sediments were noted near the tip of the biocarbon device and were easily removed with a cotton swab. Mechanical problems included devices that were too short for obese patients and the potential for kinking of the ureter at the junction of the device. The role of an indwelling stent in device success or failure could not be determined. 
TARLE I. Results of biocarbon implantation

